It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Necroptosis is a lytic, inflammatory form of cell death that not only contributes to pathogen clearance but can also lead to disease pathogenesis. Necroptosis is triggered by RIPK3-mediated phosphorylation of MLKL, which is thought to initiate MLKL oligomerisation, membrane translocation and membrane rupture, although the precise mechanism is incompletely understood. Here, we show that K63-linked ubiquitin chains are attached to MLKL during necroptosis and that ubiquitylation of MLKL at K219 significantly contributes to the cytotoxic potential of phosphorylated MLKL. The K219R MLKL mutation protects animals from necroptosis-induced skin damage and renders cells resistant to pathogen-induced necroptosis. Mechanistically, we show that ubiquitylation of MLKL at K219 is required for higher-order assembly of MLKL at membranes, facilitating its rupture and necroptosis. We demonstrate that K219 ubiquitylation licenses MLKL activity to induce lytic cell death, suggesting that necroptotic clearance of pathogens as well as MLKL-dependent pathologies are influenced by the ubiquitin-signalling system.
Necroptosis is a form of cell death characterized by membrane rupture via MLKL oligomerization, although mechanistic details remain unclear. Here, the authors show that MLKL ubiquitylation of K219 facilitates high-order membrane assembly and subsequent rupture, promoting cytotoxicity.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details










1 The Institute of Cancer Research, The Breast Cancer Now Toby Robins Research Centre, London, UK (GRID:grid.18886.3f) (ISNI:0000 0001 1271 4623)
2 Auburn University, Department of Biological Sciences, Auburn, USA (GRID:grid.252546.2) (ISNI:0000 0001 2297 8753)
3 The Institute of Cancer Research, The Breast Cancer Now Toby Robins Research Centre, London, UK (GRID:grid.18886.3f) (ISNI:0000 0001 1271 4623); University of Cologne, Institute of Biochemistry I, Medical Faculty, Joseph-Stelzmann-Str. 44, Cologne, Germany (GRID:grid.6190.e) (ISNI:0000 0000 8580 3777)
4 The Institute of Cancer Research, The Breast Cancer Now Toby Robins Research Centre, London, UK (GRID:grid.18886.3f) (ISNI:0000 0001 1271 4623); Center for Molecular Medicine Cologne (CMMC), Cologne, Germany (GRID:grid.18886.3f)
5 The Institute of Cancer Research, Functional Proteomics Group, London, UK (GRID:grid.18886.3f) (ISNI:0000 0001 1271 4623)
6 Walter and Eliza Hall Institute of Medical Research, Parkville, Australia (GRID:grid.1042.7)
7 Walter and Eliza Hall Institute of Medical Research, Parkville, Australia (GRID:grid.1042.7); University of Melbourne, Department of Medical Biology, Parkville, Australia (GRID:grid.1008.9) (ISNI:0000 0001 2179 088X)
8 Astex Pharmaceuticals, Cambridge, UK (GRID:grid.18886.3f)
9 GlaxoSmithKline, Innate Immunity Research Unit, Collegeville, USA (GRID:grid.418019.5) (ISNI:0000 0004 0393 4335); Immunology and Inflammation Research Therapeutic Area at Sanofi, Cambridge, USA (GRID:grid.418019.5)
10 GlaxoSmithKline, Innate Immunity Research Unit, Collegeville, USA (GRID:grid.418019.5) (ISNI:0000 0004 0393 4335)
11 Skidmore College, Department of Chemistry, Saratoga Springs, USA (GRID:grid.60094.3b) (ISNI:0000 0001 2270 6467)